|Bid||146.50 x 1200|
|Ask||147.54 x 900|
|Day's range||146.50 - 149.25|
|52-week range||109.16 - 157.00|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||25.96|
|Forward dividend & yield||4.04 (2.72%)|
|Ex-dividend date||24 Aug 2020|
|1y target est||N/A|
By Gina Lee
What happened Shares of Moderna (NASDAQ: MRNA) are slumping today, down 3.9% as of 11:29 a.m. EDT. The biotech reported its second-quarter results before the market opened. However, they don't appear to be the reason behind the decline in Moderna's stock.
The latest contract is priced at roughly $10 per vaccine dose produced by J&J, or around $14.50 per dose, including a previous $456 million the U.S. government promised to J&J for vaccine development in March. J&J is studying both one and two-dose regimens of its vaccine.